Betatron radiation and emittance growth in plasma wakefield accelerators

por San Miguel Claveria, P, Adli, E, Amorim, L D, An, W, Clayton, C E, Corde, S, Gessner, S, Hogan, M J, Joshi, C, Kononenko, O, Litos, M, Lu, W, Marsh, K A, Mori, W B, O'Shea, B, Raj, G, Storey, D, Vafaei-Najafabadi, N, White, G, Xu, Xinlu, Yakimenko, V
Publicado 2019

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.

por Sánchez, Cristina De Ramón, Rojas, Elizabeta A, Misiewicz-Krzeminska, Irena, Cardona-Benavides, Ignacio J, Cuadrado, Myriam, Isidro, Isabel, Jose Calasanz, Maria, García-Sanz, Ramón, Rosiñol Dachs, Laura, Martinez-Lopez, Joaquín, Baldé, Joan, Lahuerta, Juan J, San Miguel, Jesus F, Mateos, Maria-Victoria, Corchete, Luis A, Gutierrez, Norma Carmen Gutierrez
Publicado 2023

Betatron radiation and emittance growth in plasma wakefield accelerators

por San Miguel Claveria, P., Adli, E., Amorim, L. D., An, W., Clayton, C. E., Corde, S., Gessner, S., Hogan, M. J., Joshi, C., Kononenko, O., Litos, M., Lu, W., Marsh, K. A., Mori, W. B., O'Shea, B., Raj, G., Storey, D., Vafaei-Najafabadi, N., White, G., Xu, Xinlu, Yakimenko, V.
Publicado 2019

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

por Avet-Loiseau, Hervé, San-Miguel, Jesus, Casneuf, Tineke, Iida, Shinsuke, Lonial, Sagar, Usmani, Saad Z., Spencer, Andrew, Moreau, Philippe, Plesner, Torben, Weisel, Katja, Ukropec, Jon, Chiu, Christopher, Trivedi, Sonali, Amin, Himal, Krevvata, Maria, Ramaswami, Priya, Qin, Xiang, Qi, Mia, Sun, Steven, Qi, Ming, Kobos, Rachel, Bahlis, Nizar J.
Publicado 2021

Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

por Martín-Otal, Celia, Lasarte-Cia, Aritz, Serrano, Diego, Casares, Noelia, Conde, Enrique, Navarro, Flor, Sánchez-Moreno, Inés, Gorraiz, Marta, Sarrión, Patricia, Calvo, Alfonso, De Andrea, Carlos E, Echeveste, José, Vilas, Amaia, Rodriguez-Madoz, Juan Roberto, San Miguel, Jesús, Prosper, Felipe, Hervas-Stubbs, Sandra, Lasarte, Juan Jose, Lozano, Teresa
Publicado 2022

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

por Terpos, Evangelos, Musto, Pellegrino, Engelhardt, Monika, Delforge, Michel, Cook, Gordon, Gay, Francesca, van de Donk, Niels W. C. J., Ntanasis-Stathopoulos, Ioannis, Vangsted, Annette Juul, Driessen, Christoph, Schjesvold, Fredrik, Cerchione, Claudio, Zweegman, Sonja, Hajek, Roman, Moreau, Philippe, Einsele, Hermann, San-Miguel, Jesus, Boccadoro, Mario, Dimopoulos, Meletios A., Sonneveld, Pieter, Ludwig, Heinz
Publicado 2023

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autolog...

por Ocio, Enrique M., Perrot, Aurore, Bories, Pierre, San-Miguel, Jesus F., Blau, Igor W., Karlin, Lionel, Martinez-Lopez, Joaquin, Wang, Song-Yau, Bringhen, Sara, Marcatti, Magda, Mateos, María-Victoria, Rodriguez-Otero, Paula, Oliva, Stefania, Nogai, Axel, Le Roux, Nadia, Dong, Liyan, Macé, Sandrine, Gassiot, Matthieu, Fitzmaurice, Thomas, Oprea, Corina, Moreau, Philippe
Publicado 2023

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

por Einsele, Hermann, Yong, Kwee, Harrison, Simon, Mateos, Maria-Victoria, Moreau, Philippe, van de Donk, Niels W.C.J., Sidana, Surbhi, Popat, Rakesh, Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Schecter, Jordan, LI, Katherine, Zudaire, Enrique, Chen, Diana, Gilbert, Jane, Yeh, Tzu-Min, Pacaud, Lida, Patel, Nitin, Dhakal, Binod, San Miguel, Jesús
Publicado 2023

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

por Ludwig, Heinz, Beksac, Meral, Bladé, Joan, Boccadoro, Mario, Cavenagh, Jamie, Cavo, Michele, Dimopoulos, Meletios, Drach, Johannes, Einsele, Hermann, Facon, Thierry, Goldschmidt, Hartmut, Harousseau, Jean-Luc, Hess, Urs, Ketterer, Nicolas, Kropff, Martin, Mendeleeva, Larisa, Morgan, Gareth, Palumbo, Antonio, Plesner, Torben, San Miguel, Jesús, Shpilberg, Ofer, Sondergeld, Pia, Sonneveld, Pieter, Zweegman, Sonja
Publicado 2010

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth...

por Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Palumbo, Antonio, San‐Miguel, Jesus, Shpilberg, Ofer, Anderson, Kenneth, Grosicki, Sebastian, Spicka, Ivan, Walter‐Croneck, Adam, Magen, Hila, Mateos, Maria‐Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Bleickardt, Eric, Poulart, Valerie, Sheng, Jennifer, Sy, Oumar, Katz, Jessica, Singhal, Anil, Richardson, Paul
Publicado 2017

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY

por Rodriguez-Otero, P, Dholaria, B, Askari, E, Reece, D, van de Donk, N, Chari, A, Goldschmidt, H, Krishnan, A, Martin, T, Mateos, M, Morillo, D, Rodriguez, C, Rosinol, L, San-Miguel, J, Balari, A, Wäsch, R, Weisel, K, Verona, R, Lin, S, Prior, T, Wade, M, Weiss, B, Goldberg, J, Oriol, A, Hari, P
Publicado 2022

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients

por Villar, Sara, Ariceta, Beñat, Agirre, Xabier, Urribarri, Aura Daniela, Ayala, Rosa, Martínez-Cuadrón, David, Bergua, Juan Miguel, Vives, Susana, Algarra, Lorenzo, Tormo, Mar, Martínez, Pilar, Serrano, Josefina, Simoes, Catia, Herrera, Pilar, Calasanz, Maria José, Alfonso-Piérola, Ana, Paiva, Bruno, Martínez-López, Joaquín, San Miguel, Jesús F., Prósper, Felipe, Montesinos, Pau
Publicado 2022

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

por Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z., Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G., Goldschmidt, Hartmut, Reece, Donna, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, Moreau, Philippe
Publicado 2023

P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTE...

por Gonzalez-Calle, Veronica, Rodríguez-Otero, Paula, Sureda, Anna, de la Fuente, Felipe de Arriba, Reinoso Segura, Marta, Ribas, Paz, Pilar Gonzalez, Ana, Gonzalez Montes, Yolanda, Oriol, Albert, Martinez-Lopez, Joaquín, Perez, Marta Sonia Gonzalez, Garcia, Miguel Teodoro Hernandez, Sirvent Auzmendi, Maialen, Blade, Joan, Palacios, Juan José Lahuerta, San Miguel, Jesús, Mateos, Maria-Victoria
Publicado 2023

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations()

por Lopez, Aurelio, Mateos, Maria-Victoria, Oriol, Albert, Valero, Marta, Martínez, Joaquín, Lorenzo, Jose Ignacio, Perez, Montserrat, Martinez, Rafael, de Paz, Raquel, Granell, Miguel, De Arriba, Felipe, Blanchard, M. Jesús, Peñalver, Francisco Javier, Bello, Jose Luis, Martin, Maria Luisa, Bargay, Joan, Blade, Joan, Lahuerta, Juan Jose, San Miguel, Jesús F., de la Rubia, Javier
Publicado 2015

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

por López-Iglesias, Ana-Alicia, Herrero, Ana B., Chesi, Marta, San-Segundo, Laura, González-Méndez, Lorena, Hernández-García, Susana, Misiewicz-Krzeminska, Irena, Quwaider, Dalia, Martín-Sánchez, Montserrat, Primo, Daniel, Paíno, Teresa, Bergsagel, P. Leif, Mehrling, Thomas, González-Díaz, Marcos, San-Miguel, Jesús F., Mateos, María-Victoria, Gutiérrez, Norma C., Garayoa, Mercedes, Ocio, Enrique M.
Publicado 2017

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

por Puig, Noemí, Corchete-Sánchez, Luis A., Pérez-Morán, José J., Dávila, Julio, Paíno, Teresa, de la Rubia, Javier, Oriol, Albert, Martín-Sánchez, Jesús, de Arriba, Felipe, Bladé, Joan, Blanchard, María-Jesús, González-Calle, Verónica, García-Sanz, Ramón, Paiva, Bruno, Lahuerta, Juan-José, San-Miguel, Jesús F., Mateos, María-Victoria, Ocio, Enrique M.
Publicado 2020

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis

por Palladini, Giovanni, Paiva, Bruno, Wechalekar, Ashutosh, Massa, Margherita, Milani, Paolo, Lasa, Marta, Ravichandran, Sriram, Krsnik, Isabel, Basset, Marco, Burgos, Leire, Nuvolone, Mario, Lecumberri, Ramón, Foli, Andrea, Puig, Noemi, Sesta, Melania Antonietta, Bozzola, Margherita, Cascino, Pasquale, Nevone, Alice, Ripepi, Jessica, Berti, Pierpaolo, Casarini, Simona, Annibali, Ombretta, Orfao, Alberto, San-Miguel, Jesus, Merlini, Giampaolo
Publicado 2021

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

por Usmani, S, Alonso, A, Quach, H, Koh, Y, Guenther, A, Min, CK, Leleu, X, Abdallah, AO, Oriol, A, Bessemer, B, Garg, M, Sandhu, I, Weisel, K, Ocio San Miguel, E, Cavo, M, Zhou, X, Kaisermann, M, Mis, L, Williams, D, Yeakey, A, Ferron-Brady, G, Figueroa, D, Kremer, B, Gupta, I, Janowski, W
Publicado 2022

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

por Mateos, M, Hari, P, Bahlis, N, Chari, A, van de Donk, NWCJ, Dholaria, B, Garfall, AL, Goldschmidt, H, Kortüm, KM, Krishnan, A, Martin, T, Morillo, D, Oriol, A, Reece, D, Rodriguez, C, Rodríguez-Otero, P, San-Miguel, JF, Usmani, SZ, Verona, R, Lin, SXW, Prior, TJ, Wade, M, Weiss, B, Goldberg, JD, Askari, E
Publicado 2022